Clinical oncology最新文献

{"title":"RCR meetings","authors":"","doi":"10.1016/S0936-6555(25)00125-6","DOIUrl":"10.1016/S0936-6555(25)00125-6","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"42 ","pages":"Article 103870"},"PeriodicalIF":3.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paid MBP advert Advanced Educational Supervisor 210x280_01","authors":"","doi":"10.1016/j.clon.2025.103876","DOIUrl":"10.1016/j.clon.2025.103876","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"42 ","pages":"Article 103876"},"PeriodicalIF":3.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Lack of Access to Immunotherapy Medications on Survival of Lung Cancer Patients","authors":"A. Tfayli,&nbsp;L. El-Halabi,&nbsp;M.H. Hodroj,&nbsp;F. Rammal,&nbsp;A. Ghais,&nbsp;R. Tfayli,&nbsp;A. Bou Orm,&nbsp;M. Charafeddine","doi":"10.1016/j.clon.2025.103864","DOIUrl":"10.1016/j.clon.2025.103864","url":null,"abstract":"<div><h3>Aims</h3><div>Lung cancer is the leading cause of cancer-related deaths globally. With the great advancements in the treatment, the accessibility and availability of expensive treatments such as immunotherapy can be affected by economic factors. This research aims to examine how the economic crisis in Lebanon influenced the progression-free survival (PFS) of individuals with metastatic non-small cell lung cancer (NSCLC).</div></div><div><h3>Materials and Methods</h3><div>A retrospective study was conducted on 84 patients with stage IV NSCLC treated at a tertiary care center in Lebanon. Patients were divided into two groups based on their treatment period: a control group (January 2019- December 2020) and a crisis group (October 2021 - December 2022). Data on patient demographics, treatment regimens, dose densities, and PFS were collected and analysed.</div></div><div><h3>Results</h3><div>The control group had a median PFS of 11.11 months, compared to 8.40 months for the crisis group. More patients in the control had access to immunotherapy (46.9% versus 31.4%, p = 0.47). Importantly, patients who received less than 50% of the standard immunotherapy dose did not have a shorter PFS compared to those who received the full dose. Statistical analysis did not reveal a significant correlation between immunotherapy dose density and PFS (p = 0.107).</div></div><div><h3>Conclusion</h3><div>Access to immunotherapy medications in first line therapy of metastatic NSCLC has a clear impact on PFS. However, patients receiving lower doses of immune checkpoint inhibitors (ICIs) demonstrated a similar PFS compared to those receiving full doses, which challenges conventional dosing strategies and suggests that effective cancer treatment can be achieved with lower dosing regimens. These findings open the door for further investigation to explore the relationship between immunotherapy dose and PFS.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103864"},"PeriodicalIF":3.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144167786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Epithelial Ovarian Cancer: Have We Really Improved Care for Patients Aged 70 Years and Older? A 20-year Registry-based Study","authors":"J. Barben ,&nbsp;A. Mamguem Kamga ,&nbsp;V. Quipourt ,&nbsp;S. Marilier ,&nbsp;J. Niogret ,&nbsp;L. Bengrine-Lefevre ,&nbsp;T.S. Dabakuyo-Yonli","doi":"10.1016/j.clon.2025.103860","DOIUrl":"10.1016/j.clon.2025.103860","url":null,"abstract":"<div><h3>Aims</h3><div>Advanced epithelial ovarian cancer (aEOC, International Federation of Gynecology and Obstetrics(FIGO) stages IIIC-IV) is the most frequently diagnosed and lethal form of ovarian cancer. The aim of this study was to evaluate net survival (NS) over time and the differences between younger (&lt;70 years) and older (≥70 years) patients (OPs).</div></div><div><h3>Materials and Methods</h3><div>All patients with aEOC diagnosed in the French department of Côte d'Or between 01 January 1998 and 31 December 2018 were included. Two-year and 5-year NS were calculated for the two age groups over three periods: 1998 to 2004 (T1), 2005 to 2011 (T2), and 2012 to 2018 (T3).</div></div><div><h3>Results</h3><div>A total of 392 patients were included, of whom 154 (39.3%) were aged ≥70 years. Surgery-based treatment was used less frequently in OPs (58.15% vs 83.41%, <em>P</em> &lt; 0.0001) and decreased over time, notably in OPs (74.2% at T1 vs 34.8% at T3, <em>P</em> &lt; 0.001). There was a clear increase in chemotherapy alone at T3 vs T1 in OPs (odds ratio = 8.14, 95% confidence interval [CI]: [2.49-26.58], <em>P</em> &lt; 0.001). The 5-year NS was lower in OPs (23.3%, 95% CI: [17.1-31.8] vs 44.6%, 95% CI: [38.7%-51.6%], <em>P</em> &lt; 0.001) over the 20-year period. The only significant difference in NS between patients aged ≥70 years and &lt;70 years was observed during T3, 17.9% (95% CI: [10.9-29.5]) vs 42.9% (95% CI: [33.8-54.4], <em>P</em> &lt; 0.001) for 5-year NS.</div></div><div><h3>Conclusion</h3><div>NS for aEOC was lower in women aged ≥70 years, especially from 2012 to 2018. Nonoptimal treatment was also more frequent in the older age group.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103860"},"PeriodicalIF":3.2,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144167774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose Accumulation for Pelvic Stereotactic Ablative Radiotherapy Reirradiation","authors":"F. Slevin ,&nbsp;C. O'Hara ,&nbsp;J. Entwisle ,&nbsp;J. Lilley ,&nbsp;M. Nix ,&nbsp;C. Thompson ,&nbsp;M. Tyyger ,&nbsp;A.L. Appelt ,&nbsp;L.J. Murray","doi":"10.1016/j.clon.2025.103861","DOIUrl":"10.1016/j.clon.2025.103861","url":null,"abstract":"<div><h3>Aims</h3><div>Despite the increasing use of reirradiation, our understanding of appropriate normal tissue dose constraints remains limited. This is intrinsically tied to major uncertainties concerning evaluation of cumulative doses from multiple treatment courses. This study aimed to: i) retrospectively evaluate cumulative normal tissue doses in patients treated with pelvic stereotactic ablative radiotherapy (SABR) reirradiation, taking account of anatomical change and fraction size effects, and ii) produce preliminary data regarding safe cumulative normal tissue doses.</div></div><div><h3>Materials and methods</h3><div>Fifty-six patients treated with pelvic SABR reirradiation for locoregional recurrence after prior radical or (neo)adjuvant radiotherapy in the pelvis were included. Original-treatment computed tomography (CT) scans were deformably registered to the reirradiation CTs; and target volumes, organs at risk (OARs), and dose distributions were transferred from the original anatomy to the reirradiation scan. Original and reirradiation dose distributions were converted into equivalent dose in 2-Gy fractions (EQD2). Cumulative doses were calculated using deformable image registration (DIR)–based dose summation and/or summed maximum doses (D0.5 cc) for each OAR. Severe toxicity events up to 2 years post reirradiation were evaluated.</div></div><div><h3>Results</h3><div>Most patients had prostate cancer (85.7%) and were treated for pelvic nodal recurrence (75%) with a single target volume (91.1%) using a prescription dose of 30 Gy in 5 fractions (90.3%). The median time between original and reirradiation was 53 months (interquartile range [IQR]: 36-79). Based on DIR, cumulative doses in EQD2 of up to 82.8 Gy for the rectum, 110.2 Gy for the bladder, 69.8 Gy for the colon, 101.4 Gy for the sacral plexus, and 108.1 Gy for the vessels were observed. Based on summed D0.5 cc, cumulative doses of up to 111.9 Gy were delivered to the small bowel. No severe toxicity events which could be attributed to reirradiation were observed.</div></div><div><h3>Conclusions</h3><div>This study has demonstrated feasibility of per-voxel anatomically and radiobiologically appropriate 3-dimensional evaluation of cumulative normal tissue doses in patients previously treated with pelvic SABR reirradiation. No toxicity events could be attributed to the cumulative or reirradiation doses delivered.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103861"},"PeriodicalIF":3.2,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimising Axillary Lymph Node Delineation for Consistent Dosimetry in Breast Radiotherapy","authors":"Q. Xu","doi":"10.1016/j.clon.2025.103859","DOIUrl":"10.1016/j.clon.2025.103859","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103859"},"PeriodicalIF":3.2,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OncoFlash - Research Updates in a Flash! (June 2025)","authors":"C.W. Bleaney ,&nbsp;C. Crockett","doi":"10.1016/j.clon.2025.103858","DOIUrl":"10.1016/j.clon.2025.103858","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"42 ","pages":"Article 103858"},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Employing Digital Health for the Follow-up and Monitoring of Patients Undergoing Anticancer Treatment: First Results of Satelia®Onco on Patient Satisfaction and Recommendations of Use in France","authors":"M. Zysman ,&nbsp;A. Creisson ,&nbsp;G. Ghrenassia ,&nbsp;S. Nisse-Durgeat ,&nbsp;A. Boyer ,&nbsp;M. Matranga ,&nbsp;C. Bedel ,&nbsp;N. Pages ,&nbsp;J. Ducray","doi":"10.1016/j.clon.2025.103856","DOIUrl":"10.1016/j.clon.2025.103856","url":null,"abstract":"<div><h3>Aims</h3><div>Telemedicine involves the use of information communication technologies and aims to support disease management, enhance treatment adherence, and improve patients’ quality of life (QoL). Despite its growing advantages, many challenges persist in its widespread adoption, which may be influenced by the health status and digital literacy of users. The objective of this study was to explore patient satisfaction with a web application used for the monitoring and follow-up of anticancer treatment.</div></div><div><h3><em>Material and methods</em></h3><div>A descriptive, multicentric, survey-based study was conducted with adult patients undergoing treatment in two oncology centres in France from October 2, 2023 to December 11, 2023. The online survey included 15 items covering the perceived usefulness, ease of use, and impact on QoL of a telemedicine solution used to monitor the side effects of anticancer treatment. Analysis was stratified by cancer type, duration of use, and age group.</div></div><div><h3><em>Results</em></h3><div>A total of 104 patients participated in the study (response rate: 33.0%). Most patients were female (64.4%), aged 46–65 years (42.3%), and were receiving treatment for lung cancer (50.0%) or breast cancer (39.4%). Remote monitoring was predominantly used for less than three months (39.4%), followed by more than six months (34.6%). Patient satisfaction and recommendation rates were high across age groups, cancer type, and durations of use (82.7%, respectively). Patients with breast cancer (82.9%) and lung cancer (82.7%) reported being absolutely satisfied. Positive feedback encompassed ease of access, comprehension of follow-up questions, and perceived usefulness. Older patients reported slightly lower scores for ease of use and improvement in QoL.</div></div><div><h3><em>Conclusion</em></h3><div>To our knowledge, these findings are among the first preliminary results concerning patient satisfaction for telemedicine use to monitor the side effects of anticancer treatment in clinical practice settings in France.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103856"},"PeriodicalIF":3.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Survival Outcomes and Recurrence Patterns in Oral Cavity Squamous Cell Carcinoma (OCSCC) Patients Treated With Curative Intent Either With Adjuvant or Definitive (Chemo)radiotherapy","authors":"K. Oguejiofor ,&nbsp;S. Ramkumar ,&nbsp;A.-A. Nabi ,&nbsp;K. Moutasim ,&nbsp;R.P. Singh ,&nbsp;S. Sharma ,&nbsp;M. Ethunandan ,&nbsp;I.S. Boon","doi":"10.1016/j.clon.2025.103855","DOIUrl":"10.1016/j.clon.2025.103855","url":null,"abstract":"<div><h3>Aims</h3><div>To assess the survival outcome and recurrence patterns of locally advanced oral cavity squamous cell carcinoma (LA-OCSCC) treated with radical surgery followed by adjuvant or definitive upfront (chemo)radiotherapy.</div></div><div><h3>Materials and methods</h3><div>This is a single United Kingdom cancer centre retrospective analysis on LA-OCSCC treated with curative intent. All OCSCC patients treated between 2012 and 2022 were included with groups treated with either postoperative adjuvant (chemo)-radiotherapy or definitive (chemo)radiotherapy. Patients who recurred before starting adjuvant treatments were excluded.</div></div><div><h3>Results</h3><div><em>Patient characteristics</em>: Ninety-nine (73.9%) patients were treated with primary surgery followed by adjuvant (chemo)radiotherapy and 35 (26.1%) patients treated in the definitive group, respectively. <em>Survival</em>: The median progression-free survival was 17 months and 15 months for adjuvant and definitive groups, respectively (<em>P</em> value of 0.947). Median overall survival was 61 months and 43 months for adjuvant and definitive groups, respectively (<em>P</em> value of 0.154). Smoking history is an independent negative predictor for survival. <em>Recurrence</em>: Median time to local and distant recurrence was 17 months and 15 months, respectively. In the adjuvant group, the local recurrence rate is 26% and the distant recurrence rate is 32%, compared with the definitive group at 26% and 34%, respectively. The rate of recurrence is highest in the first two years after diagnosis. Distant recurrence in LA-OCSCC can happen without prior local-regional recurrence.</div></div><div><h3>Conclusion</h3><div>Patients with surgically resectable LA-OCSCC patients treated with primary radical surgery followed by adjuvant (chemo)radiotherapy had better survival outcomes compared with patients treated with upfront definitive (chemo)radiotherapy. The pattern of recurrence of LA-OCSCC is aggressive and without curative surgery the rate of survival is poorer.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103855"},"PeriodicalIF":3.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144124155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of Adverse Reactions of Radiopharmaceuticals.","authors":"M R Mititelu, V Stanulovic, A Mitoi, S Bucurica, M Hodolic, K Kairemo","doi":"10.1016/j.clon.2025.103857","DOIUrl":"https://doi.org/10.1016/j.clon.2025.103857","url":null,"abstract":"<p><strong>Aims: </strong>Theranostics utilizes the nuclear properties of radioactive isotopes, especially for molecular imaging and targeted therapy. Radiopharmaceuticals (RPs), which combine a pharmaceutical ligand with a radionuclide, enable accurate diagnosis and treatment of various diseases through modalities such as PET and SPECT imaging. The aim of this papare is to review adverse reactions associated with diagnostic and therapeutic radiopharmaceuticals, with an emphasis on their severity and clinical management.</p><p><strong>Materials and methods: </strong>This review evaluates documented adverse effects (AEs) related to RPs used in nuclear medicine imaging (PET and SPECT) and radionuclide therapy, focusing on their severity and clinical management strategies. It also considers the mechanisms of RPs toxicity, distinguishes between general and specific AEs, and highlights the limitations in current adverse drug reaction (ADR) assessment tools. The methodology used was the research and synthesis of most relevant published literature data; most relevant papers were synthesized regarding the reporting system of ARs and categorized by the specific and systemic adverse effects of RPs.</p><p><strong>Results: </strong>Side effects from diagnostic RPs are relatively rare and typically minimal. Therapeutic RPs, selected for their high-energy radiation properties, can cause DNA damage to malignant cells while minimizing harm to healthy tissues. Although adverse effects do occur, they are generally fewer and less severe compared to conventional therapies. Severe toxicity is rare and often preventable. Both patient- and provider-reported ADRs offer important safety insights, though validated assessment instruments remain limited.</p><p><strong>Conclusion: </strong>Radionuclide therapy offers a targeted approach that is a less invasive alternative to conventional treatments with a favorable safety profile. Continued evaluation of adverse reactions and the development of standardized ADR assessment tools are essential for improving patient outcomes and RP safety monitoring.</p>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":" ","pages":"103857"},"PeriodicalIF":3.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}